CN109293606B - 2,5-双取代呋喃衍生物及其作为sirt蛋白抑制剂在药物制备中的用途 - Google Patents
2,5-双取代呋喃衍生物及其作为sirt蛋白抑制剂在药物制备中的用途 Download PDFInfo
- Publication number
- CN109293606B CN109293606B CN201811386729.1A CN201811386729A CN109293606B CN 109293606 B CN109293606 B CN 109293606B CN 201811386729 A CN201811386729 A CN 201811386729A CN 109293606 B CN109293606 B CN 109293606B
- Authority
- CN
- China
- Prior art keywords
- reaction
- substituted
- compound
- phenyl
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 16
- 229940121649 protein inhibitor Drugs 0.000 title claims abstract description 6
- 239000012268 protein inhibitor Substances 0.000 title claims abstract description 6
- 229940079593 drug Drugs 0.000 title claims description 10
- 102000011990 Sirtuin Human genes 0.000 title abstract description 18
- 108050002485 Sirtuin Proteins 0.000 title abstract description 18
- -1 2, 5-disubstituted furan Chemical class 0.000 title abstract description 16
- 238000002360 preparation method Methods 0.000 title abstract description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 44
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 9
- 208000030159 metabolic disease Diseases 0.000 claims abstract description 9
- 238000006243 chemical reaction Methods 0.000 claims description 57
- 239000000047 product Substances 0.000 claims description 24
- 108010041216 Sirtuin 2 Proteins 0.000 claims description 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 15
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 11
- 102100031455 NAD-dependent protein deacetylase sirtuin-1 Human genes 0.000 claims description 10
- 108010041191 Sirtuin 1 Proteins 0.000 claims description 10
- 239000003054 catalyst Substances 0.000 claims description 9
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 8
- CUYKNJBYIJFRCU-UHFFFAOYSA-N 3-aminopyridine Chemical compound NC1=CC=CN=C1 CUYKNJBYIJFRCU-UHFFFAOYSA-N 0.000 claims description 8
- 239000007795 chemical reaction product Substances 0.000 claims description 8
- 239000003112 inhibitor Substances 0.000 claims description 8
- 239000000376 reactant Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 claims description 7
- FXORZKOZOQWVMQ-UHFFFAOYSA-L dichloropalladium;triphenylphosphane Chemical group Cl[Pd]Cl.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 FXORZKOZOQWVMQ-UHFFFAOYSA-L 0.000 claims description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Substances O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 5
- 229910052751 metal Inorganic materials 0.000 claims description 5
- 239000002184 metal Substances 0.000 claims description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical group [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 208000030090 Acute Disease Diseases 0.000 claims description 3
- 239000004327 boric acid Substances 0.000 claims description 3
- YCBJOQUNPLTBGG-UHFFFAOYSA-N ethyl 4-iodobenzoate Chemical compound CCOC(=O)C1=CC=C(I)C=C1 YCBJOQUNPLTBGG-UHFFFAOYSA-N 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 230000000626 neurodegenerative effect Effects 0.000 claims description 3
- 125000001424 substituent group Chemical group 0.000 claims description 3
- 238000006460 hydrolysis reaction Methods 0.000 claims description 2
- 229910052763 palladium Inorganic materials 0.000 claims description 2
- 102000000477 Sirtuin 2 Human genes 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000004202 aminomethyl group Chemical class [H]N([H])C([H])([H])* 0.000 abstract description 5
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 230000004770 neurodegeneration Effects 0.000 abstract description 5
- 208000015122 neurodegenerative disease Diseases 0.000 abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 87
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 54
- 238000001035 drying Methods 0.000 description 41
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 36
- 238000004440 column chromatography Methods 0.000 description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 21
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 20
- 239000012043 crude product Substances 0.000 description 19
- 239000007787 solid Substances 0.000 description 19
- 230000015572 biosynthetic process Effects 0.000 description 18
- 238000003756 stirring Methods 0.000 description 18
- 238000003786 synthesis reaction Methods 0.000 description 18
- 238000010438 heat treatment Methods 0.000 description 17
- 238000010992 reflux Methods 0.000 description 17
- 238000005160 1H NMR spectroscopy Methods 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 238000004809 thin layer chromatography Methods 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 238000009987 spinning Methods 0.000 description 14
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 12
- 102100022913 NAD-dependent protein deacetylase sirtuin-2 Human genes 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 9
- 239000012044 organic layer Substances 0.000 description 9
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
- 239000012046 mixed solvent Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- 102000003964 Histone deacetylase Human genes 0.000 description 6
- 108090000353 Histone deacetylase Proteins 0.000 description 6
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000006196 deacetylation Effects 0.000 description 5
- 238000003381 deacetylation reaction Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 125000001072 heteroaryl group Chemical group 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 3
- 101000636713 Homo sapiens E3 ubiquitin-protein ligase NEDD4 Proteins 0.000 description 3
- 101000616727 Homo sapiens NAD-dependent protein deacylase sirtuin-5, mitochondrial Proteins 0.000 description 3
- 102100021839 NAD-dependent protein deacylase sirtuin-5, mitochondrial Human genes 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- ZDHXKXAHOVTTAH-UHFFFAOYSA-N trichlorosilane Chemical compound Cl[SiH](Cl)Cl ZDHXKXAHOVTTAH-UHFFFAOYSA-N 0.000 description 3
- 239000005052 trichlorosilane Substances 0.000 description 3
- LUBJCRLGQSPQNN-UHFFFAOYSA-N 1-Phenylurea Chemical compound NC(=O)NC1=CC=CC=C1 LUBJCRLGQSPQNN-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 230000005971 DNA damage repair Effects 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102100031918 E3 ubiquitin-protein ligase NEDD4 Human genes 0.000 description 2
- 102000003893 Histone acetyltransferases Human genes 0.000 description 2
- 108090000246 Histone acetyltransferases Proteins 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000012295 chemical reaction liquid Substances 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 230000000850 deacetylating effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 230000004049 epigenetic modification Effects 0.000 description 2
- 230000007705 epithelial mesenchymal transition Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- PZJSZBJLOWMDRG-UHFFFAOYSA-N furan-2-ylboronic acid Chemical compound OB(O)C1=CC=CO1 PZJSZBJLOWMDRG-UHFFFAOYSA-N 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 230000035322 succinylation Effects 0.000 description 2
- 238000010613 succinylation reaction Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- HBENZIXOGRCSQN-VQWWACLZSA-N (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylpentan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@H]3[C@@]5(OC)CC[C@@]2([C@@]43CC1)C[C@@H]5[C@](C)(O)C(C)(C)CC)CC1CC1 HBENZIXOGRCSQN-VQWWACLZSA-N 0.000 description 1
- FANCTJAFZSYTIS-IQUVVAJASA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-4-(phenylsulfonimidoyl)butan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C\1C([C@@H](O)C[C@H](O)C/1)=C)C)CS(=N)(=O)C1=CC=CC=C1 FANCTJAFZSYTIS-IQUVVAJASA-N 0.000 description 1
- SHAHPWSYJFYMRX-GDLCADMTSA-N (2S)-2-(4-{[(1R,2S)-2-hydroxycyclopentyl]methyl}phenyl)propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C[C@@H]1[C@@H](O)CCC1 SHAHPWSYJFYMRX-GDLCADMTSA-N 0.000 description 1
- KAFZOLYKKCWUBI-HPMAGDRPSA-N (2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-3-amino-2-[[(2s)-2-[[(2s)-2-(3-cyclohexylpropanoylamino)-4-methylpentanoyl]amino]-5-methylhexanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]butanediamide Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H](CCC(C)C)C(=O)N[C@@H](CN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(N)=O)C(=O)CCC1CCCCC1 KAFZOLYKKCWUBI-HPMAGDRPSA-N 0.000 description 1
- FOLCUFKJHSQMEL-BIXPGCQOSA-N (4-butylcyclohexyl) N-[(2S)-4-methyl-1-oxo-1-[[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]pentan-2-yl]carbamate Chemical compound CCCCC1CCC(CC1)OC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C[C@@H]2CCNC2=O)C=O FOLCUFKJHSQMEL-BIXPGCQOSA-N 0.000 description 1
- VIMMECPCYZXUCI-MIMFYIINSA-N (4s,6r)-6-[(1e)-4,4-bis(4-fluorophenyl)-3-(1-methyltetrazol-5-yl)buta-1,3-dienyl]-4-hydroxyoxan-2-one Chemical compound CN1N=NN=C1C(\C=C\[C@@H]1OC(=O)C[C@@H](O)C1)=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 VIMMECPCYZXUCI-MIMFYIINSA-N 0.000 description 1
- JUWYQISLQJRRNT-UHFFFAOYSA-N (5-formylfuran-2-yl)boronic acid Chemical compound OB(O)C1=CC=C(C=O)O1 JUWYQISLQJRRNT-UHFFFAOYSA-N 0.000 description 1
- SVENPFFEMUOOGK-SDNWHVSQSA-N (e)-2-cyano-3-[5-(2,5-dichlorophenyl)furan-2-yl]-n-quinolin-5-ylprop-2-enamide Chemical compound ClC1=CC=C(Cl)C(C=2OC(\C=C(/C#N)C(=O)NC=3C4=CC=CN=C4C=CC=3)=CC=2)=C1 SVENPFFEMUOOGK-SDNWHVSQSA-N 0.000 description 1
- FDUGOYTWYJZNNP-UHFFFAOYSA-N 4-amino-2-fluorobenzonitrile Chemical compound NC1=CC=C(C#N)C(F)=C1 FDUGOYTWYJZNNP-UHFFFAOYSA-N 0.000 description 1
- CBAXYISWNGGXOZ-UHFFFAOYSA-N 5-bromo-2-methylpyridin-3-amine Chemical compound CC1=NC=C(Br)C=C1N CBAXYISWNGGXOZ-UHFFFAOYSA-N 0.000 description 1
- 102100026882 Alpha-synuclein Human genes 0.000 description 1
- 101100069026 Arabidopsis thaliana GK-2 gene Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000007067 DNA methylation Effects 0.000 description 1
- 102100034009 Glutamate dehydrogenase 1, mitochondrial Human genes 0.000 description 1
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 1
- 102100038104 Glycogen synthase kinase-3 beta Human genes 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 101000870042 Homo sapiens Glutamate dehydrogenase 1, mitochondrial Proteins 0.000 description 1
- 101000616738 Homo sapiens NAD-dependent protein deacetylase sirtuin-6 Proteins 0.000 description 1
- 101000863629 Homo sapiens NAD-dependent protein lipoamidase sirtuin-4, mitochondrial Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 1
- 102100021840 NAD-dependent protein deacetylase sirtuin-6 Human genes 0.000 description 1
- 102100030709 NAD-dependent protein lipoamidase sirtuin-4, mitochondrial Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108020004422 Riboswitch Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 108090000185 alpha-Synuclein Proteins 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
- WARCRYXKINZHGQ-UHFFFAOYSA-N benzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1 WARCRYXKINZHGQ-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 230000004656 cell transport Effects 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000011365 genetic imprinting Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 230000017538 malonylation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229940101270 nicotinamide adenine dinucleotide (nad) Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- PFGVNLZDWRZPJW-OPAMFIHVSA-N otamixaban Chemical compound C([C@@H](C(=O)OC)[C@@H](C)NC(=O)C=1C=CC(=CC=1)C=1C=C[N+]([O-])=CC=1)C1=CC=CC(C(N)=N)=C1 PFGVNLZDWRZPJW-OPAMFIHVSA-N 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- 239000003279 phenylacetic acid Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000008791 toxic response Effects 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了式(I)所示的2,5‑双取代呋喃衍生物,该2,5‑双取代呋喃衍生物主要为2‑位取代胺甲基,5‑位取代苯基,还公开了所述化合物的制备方法及作为SIRT蛋白抑制剂在药物制备中的用途。本发明的化合物可用于治疗多种疾病,如肿瘤、神经退行性疾病、代谢性疾病等。
Description
技术领域
本发明属于有机合成药物技术领域,特别涉及2,5-双取代呋喃衍生物及其制备方法和在药物制备中的用途,该2,5-双取代呋喃衍生物主要为2-位取代胺甲基,5-位取代苯基。
背景技术
DNA在不改变序列的前提下,其表达水平与功能也可发生稳定遗传的变化,这一现象被称为表观遗传。截至目前,已经研究的表观遗传修饰包括:DNA甲基化、组蛋白修饰、染色质重塑、基因印迹、核糖开关等。组蛋白(H1、H2A、H2B、H3和H4)的赖氨酸或精氨酸易受甲基化、乙酰化、磷酸化、泛素化等修饰,其中乙酰化是最重要的修饰。这一表观遗传修饰主要受组蛋白乙酰化转移酶(HAT)和去乙酰化酶(HDAC)共同调控。目前已报道的人类组蛋白去乙酰化酶共18种,其中HDAC1-11包含同源性较高的催化核心结构域,其催化作用依赖于Zn2+的直接参与,而Sirtuin(SIRT),即SIRT1-7,是一类完全区别于HDAC1-11的非典型组蛋白去乙酰化酶家族,它们催化底物的去乙酰化作用依赖于NAD+的直接参与。由于催化机制的特异性及近年来大量高水平研究表明SIRT家族还能有效催化大量底物的去长链脂肪酰化、去琥珀酰化和去丙二酰化等,SIRT家族的相关研究已成为表观遗传学研究的热门领域之一。
基于氨基酸序列的相似性,哺乳动物体内SIRT蛋白共分为四个亚系列,其中,SIRT1-3属于第一系列,具有较强的脱乙酰化作用,也具有一定脱长链脂肪酸酰化的作用;SIRT4和SIRT5分别属于第二和第三系列,其中SIRT5具有较强的脱丙二酰化和琥珀酰化作用;SIRT6、SIRT 7同属于第四系列,它们几乎无脱乙酰化作用或只有极弱的脱乙酰化作用。研究显示,多种SIRT蛋白在DNA损伤修复,细胞存活和凋亡,能量代谢等细胞进程方面发挥着重要作用,与肿瘤、神经退行性疾病、代谢性疾病等的发生发展及预后密切相关。例如,Liu等人发现SIRT2可与泛素-蛋白连接酶NEDD4的核心启动子结合,催化H4K16去乙酰化,从而抑制NEDD4基因的表达,进而阻断NEDD4介导的癌基因蛋白Myc的降解;Chen等人发现SIRT2在肝细胞癌(HCC)患者的癌细胞中明显高表达,并可通过去乙酰化PKB来上调GSK-3β/β-catenin信号通路介导的上皮-间质转化(EMT),从而促进HCC细胞的转运和侵袭;Wang等人发现SIRT5的高表达与结肠癌的预后差密切相关,通过对GLUD1去戊二酰化,提高糖酵解和谷氨酰胺代谢,从而促进结肠癌的发生发展;此外,Kazantsev等人发现SIRT2抑制剂AGK2在帕金森模型中不仅能逆转α-突触核蛋白介导的毒性反应,还能保护多巴胺能神经免遭坏死,从而改善帕金森症状。鉴于此,SIRT被认为是多种疾病的重要药物靶标,其抑制剂研究具有重要意义。
发明内容
本发明的目的在于提供一类新型的SIRT抑制剂类药物,其结构为2,5-双取代呋喃衍生物,该2,5-双取代呋喃衍生物主要为2-位取代胺甲基,5-位取代苯基。
具体地说,本发明提供了一种化合物或其药学上可接受的盐或其溶剂合物,所属化合物的结构如式(I)所示:
其中:
R1为取代苯基,所述取代苯基被一个或多个选自-COOH、-COOR4、-OH、-CX3、-CHX2、-CH2X的取代基所取代;R4选自C1~C6烷基;
R2选自H或-OH;
R3选自取代或非取代苯基、-COR5、-NHR6、-SO2R7、-CSNHR8,所述取代苯基被一个或多个选自-CH2COOH、-OH、-CX3、-CHX2、-CH2X、C1~C6烷基的取代基所取代;
R5选自取代或非取代芳基或杂芳基、-NHR9、-(CH2)aR10;所述取代芳基或杂芳基分别独立地被一个或多个选自-CH2COOH、-OH、-CX3、-CHX2、-CH2X、C1~C6烷基的取代基所取代;
R6选自-COR11、-NHR12;
R7、R8选自苯基;
R9选自取代或非取代芳基或杂芳基,所述取代芳基或杂芳基分别独立地被一个或多个选自-X、-CN、-CX3、-CHX2、-CH2X、C1~C6烷基的取代基所取代;
R10、R11、R12均选自苯基;
X表示F、Cl、Br或I;a=1或2。
进一步地,所述C1~C6烷基选自乙基。
进一步地,所述R1中,苯基取代基为-COOH。
进一步地,所述R2选自H。
进一步地,所述R9中,杂芳基选自吡啶。
进一步地,所述的化合物或其药学上可接受的盐或其溶剂合物,所述化合物选自如下化合物之一:
本发明还提供了上述化合物的制备方法,其特征在于:反应步骤如下:
其中,包括以下步骤:
S1:取对碘苯甲酸乙酯与5-甲醛基呋喃-2-硼酸在碱性条件金属催化剂下反应,得到产物留作下一步的反应物;
S2:将上一步反应产物与盐酸羟胺反应,得到产物留作下一步的反应物;
S3:将上一步反应产物进行还原,得到产物留作下一步的反应物;
S4:将上一步反应产物与3-氨基吡啶、二(三氯甲基)碳酸酯反应,得到产物留作下一步的反应物;
S5:将上一步反应产物在碱性条件下进行水解反应,即得。
进一步地,所述金属催化剂为钯催化剂,优选为三苯基膦二氯化钯。
本发明还提供了所述化合物、或其药学上可接受的盐、或其溶剂合物在制备沉默信息调节因子2蛋白抑制剂类药物上的用途。
其中,所述沉默信息调节因子2蛋白抑制剂类药物是SIRT1和SIRT2抑制剂类药物。
其中,所述药物是治疗或预防代谢性疾病、肿瘤或神经退行性急性病的药物。所述代谢疾病包括糖尿病。
本发明还提供了一种药物组合物,它是以本发明提供的化合物、或其药学上可接受的盐、或其前药、或其溶剂合物为活性成分,加上药学上可接受的辅料制备而成的制剂。
其中,所述组合物是治疗或预防代谢性疾病、肿瘤或神经退行性急性病的药物。
所述前药是前述化合物的衍生物,它们自身可能具有较弱的活性或甚至没有活性,但是在给药后,在生理条件下(例如通过代谢、溶剂分解或另外的方式)被转化成相应的生物活性形式。
所述的制剂可以包括注射剂或口服制剂。
本发明中的关键中间体和化合物进行分离和纯化,所使用的方式是有机化学中常用的分离和纯化方法。
本发明的一种或多种化合物可以彼此联合使用,也可选择将本发明的化合物与任何其它的活性试剂结合使用,用于制备SIRT抑制剂。如果使用的是一组化合物,则可将这些化合物同时、分别或有序地对受试对象进行给药。
本发明所述药学上可接受的辅料,是指除活性成分以外包含在剂型中的物质。
本发明中所用的术语“C1-C6烷基”指1至6个碳原子的直链或支链烷烃。例如,甲基,乙基,异丙基,叔丁基和己基。
本文所用的术语“取代”是指分子中的氢原子被其它不同的原子或分子所替换。
本发明中“芳基”指全碳原子形成的具有芳香性的不饱和环。
本发明中的“芳杂基”指包含至少一个杂原子的具有芳香性的不饱和环;其中杂原子指氮原子、氧原子、硫原子。
SIRT1和SIRT2蛋白具有较强的脱乙酰化作用,在DNA损伤修复,细胞存活和凋亡,能量代谢等细胞进程方面发挥着重要作用,其抑制剂可以用于治疗多种疾病,如肿瘤、神经退行性疾病、代谢性疾病。本发明提供的2,5-双取代呋喃衍生物,该2,5-双取代呋喃衍生物主要为2-位取代胺甲基,5-位取代苯基,它们是SIRT1和SIRT2的抑制剂,可以用于治疗多种疾病,如肿瘤、神经退行性疾病、代谢性疾病等。
显然,根据本发明的上述内容,按照本领域的普通技术知识和惯用手段,在不脱离本发明上述基本技术思想前提下,还可以做出其它多种形式的修改、替换或变更。
以下通过实施例形式的具体实施方式,对本发明的上述内容再作进一步的详细说明。但不应将此理解为本发明上述主题的范围仅限于以下的实例。凡基于本发明上述内容所实现的技术均属于本发明的范围。
具体实施方式
本发明具体实施方式中使用的原料、设备均为已知产品,通过购买市售产品获得。
实施例1、5-甲醛基呋喃-2-对苯甲酸乙酯的合成
将化合物A对碘苯甲酸乙酯(2186.4μL,12.96mmol)加入反应瓶中,乙腈:水=1:1共20mL加入三苯基膦二氯化钯(456.1mg,0.649mmol),碳酸钠(2754.95mg,25.99mmol),B5-甲醛基呋喃-2-硼酸(2000mg,14.29mmol)60℃回流60min,反应结束,乙腈旋干加水pH至7,EA萃取柱层析分离得X-1共1239.9mg,收率为73.8%。
实施例2、WZY-ZX-0501的合成
化合物X-1(262.74mg1.17mmol),a(119.85μL,1.287mmol),二氢吡啶酯(415mg1.64mmol),三氟乙酸(43.584μL 0.585mmol),加入反应瓶中,DCM 45℃回流6h。反应液旋干,加饱和碳酸氢钠溶液调pH至7-8,EA萃取,旋干,柱层析分离提纯得产物。收358.6mg,收率94.45%。
将X-2(358.6mg1.1mmol)溶于EtOH:H2O1:1,加入NaOH(221.1mg5.53mmol),升温至100℃回流,0.5-1h,反应结束旋干乙醇,加水调pH至5-6,EA萃取,旋干,柱层析加重结晶收140.4mg,收率43.39%。
1H NMR(400MHz,DMSO-d6)δ7.96(d,J=7.60Hz,2H),7.75(d,J=7.60Hz,2H),7.08(t,J=13.20Hz,2H),7.03(s,1H),6.68(d,J=7.60Hz,2H),6.55(t,J=13.20Hz,1H),6.45(s,1H),6.16(s,1H)ppm.
13C NMR(100MHz,DMSO-d6)δ167.4,155.2,151.5,148.7,134.6,130.5,129.4,129.3,123.4,116.7,112.9,110.1,109.4,40.6ppm.
实施例3、WZY-ZX-0500的合成
X-3:化合物X-1(100mg,0.446mmol)加入反应瓶中,加入三氯氢硅(44.74μL0.446mmol),AcCl(31.71μL 0.446mmol),DCM溶解。加入b苯基脲(182.14 1.34mmol)搅拌30min,反应结束将反应液旋干,加饱和碳酸氢钠溶液调pH至7-8,EA萃取,旋干,柱层析分离提纯得产物。收142.3mg,收率42.29%。
WZY-ZX-0500:将X-3(70mg 0.185mmol)溶于EtOH:H2O1:1,加入NaOH(37.04mg,0.926mmol),升温至100℃回流0.5-1h,反应结束旋干乙醇,加水调pH至5-6,EA萃取,旋干,柱层析加重结晶收40mg,收率67.09%。
1H NMR(400MHz,DMSO-d6)δ9.28(s,1H),7.99(d,J=8.00Hz,2H),7.70(d,J=8.00Hz,2H),7.85(d,J=8.00Hz,2H),7.38(s,1H),7.21(t,J=15.60Hz,2H),6.95(d,J=3.20Hz,1H),6.88(t,J=14.40Hz,1H),6.40(d,J=2.80Hz,1H),4.37(d,J=5.20Hz,2H)ppm.
实施例4、ZX-0731的合成
ZX-0731:化合物X-1(200mg 0.89mmol),加入反反应瓶中,加入三氯氢硅(89.28μL0.89mmol)AcCl(62.28μL 0.89mmol),DCM溶解。加入c苯甲酰肼(364.28mg,2.67mmol),搅拌30min,反应结束,反应液旋干,加饱和碳酸氢钠溶液调pH至7-8,EA萃取,旋干,柱层析分离提纯得产物。收160.3mg,收率52.29%。
1H NMR(400MHz,DMSO-d6)δ11.93(s,1H),8.44(s,1H),8.05(d,J=8.40Hz,2H),7.93(d,J=7.60Hz,4H),7.62(t,J=14.80Hz,1H)7.55(d,J=14.40Hz,1H),7.35(d,J=2.80Hz,1H),7.13(q,J=2.80Hz,2H),4.35(q,J=6.80Hz,2H)1.35(t,J=14.00Hz,3H)ppm.
实施例5、ZX-0724的合成
ZX-0724:化合物X-1(200mg 0.89mmol),加入反反应瓶中,加入三氯氢硅(89.28μL0.89mmol)AcCl(62.28μL 0.89mmol),DCM溶解。加入d苯基胺基脲(405.14mg,2.68mmol),搅拌30min,反应结束,反应液旋干,加饱和碳酸氢钠溶液调pH至7-8,EA萃取,旋干,柱层析分离提纯得产物。收167.5mg,收率49.56%。
1H NMR(400MHz,DMSO-d6)δ10.88(s,1H),8.81(s,1H),8.03(d,J=8.80Hz,2H),7.97(d,J=8.40Hz,2H),7.94(s,1H),7.67(d,J=8.40Hz,2H),7.33(d,J=3.60Hz,1H),7.31(d,J=8.80Hz,2H),7.15(d,J=3.60Hz,1H),7.04(d,J=14.80Hz,1H),4.34(q,J=7.20Hz,2H),1.34(t,J=14.00Hz,4H)ppm.
13C NMR(100MHz,DMSO-d6)δ165.8,153.3,153.2,150.9,139.4,134.1,131.0,130.3,129.1,129.0,124.3,123.0,120.2,114.7,111.2,61.3,14.6ppm.
实施例6、中间体X-5的合成
X-5:化合物X-1(518.7mg2.31mmol),加入反反应瓶中,加入盐酸羟胺(192.88mg2.78mmol)醋酸钠(227.65mg2.78mmol),EtOH溶解,回流,搅拌30min,反应结束,反应液旋干,加水加EA萃取,旋干,加EtOH溶解加Zn(125.43mg1.93mmol)HCl(1.286mL3Ml)回流,反应结束,旋干EtOH,调pH至8-9加EA硅藻土过滤再EA萃取,柱层析时加三乙胺润柱,分离提纯得产物。收300.3mg,收率56.27%。
实施例7、WZY-ZX-0520的合成
WZY-ZX-0520:1)将e苯甲酸(58.15mg,0.48mmol)加入反应瓶,用DCM溶解,搅拌下加入EDCI(91.42mg,0.48mmol),HOBT(69.52mg,0.48mmol),X-5(100mg,0.43mmol)然后室温下反应过夜,旋干,加饱和碳酸氢钠溶液调pH至7-8,,EA萃取,经柱层析得产品X-6.投下一步。
2)将X-6溶于EtOH:H2O1:1,加入NaOH(51.6mg,1.29mmol),升温至70℃回流,0.5-1h,反应结束旋干乙醇,加1N盐酸调pH至5-6,EA萃取,旋干,柱层析加重结晶收102.9mg,收率74.42%
1H NMR(400MHz,DMSO-d6)δ9.09(t,J=8.4Hz,1H),7.98(d,J=8.40Hz,2H),7.90(d,J=1.60Hz,2H),7.79(d,J=8.80Hz,2H),7.55(m,1H),7.49(m,2H),7.08(d,J=2.40Hz,1H),6.47(d,J=3.20Hz,1H),4.58(d,J=5.60Hz,2H)ppm.
13C NMR(100MHz,DMSO-d6)δ167.5,166.7,154.2,151.6,134.5,134.5,131.9,130.5,129.5,128.8,127.8,123.5,110.1,109.5,36.8ppm.
实施例8、WZY-ZX-0521的合成
WZY-ZX-0521:1)将e(64.83mg,0.48mmol)加入反应瓶,用DCM溶解,搅拌下加入EDCI(91.43mg,0.43mmol),HOBT(69.52mg,0.48mmol),X-5(100mg,0.43mmol)然后室温下反应过夜,旋干,加饱和碳酸氢钠溶液调pH至7-8,EA萃取,经柱层析得产品X-7.投下一步。
2):将X-7溶于EtOH:H2O1:1,加入NaOH(51.6mg,1.29mmol),升温至70℃回流,0.5-1h,反应结束旋干乙醇,加加1N盐酸调pH至5-6,EA萃取,旋干,柱层析加重结晶收133.70mg,收率92.72%
1H NMR(400MHz,DMSO-d6)δ12.98(s,1H),8.65(t,J=8.80Hz,1H),7.98(d,J=8.80Hz,2H),7.75(d,J=8.40Hz,2H),7.30(d,J=4.40Hz,4H),7.23(m,1H),7.05(d,J=3.20Hz,1H),6.38,(d,J=3.20Hz,1H),4.37(d,J=5.60Hz,2H),3.49(s,2H)ppm.
13C NMR(100MHz,DMSO-d6)δ170.6,167.4,154.0,151.7,136.8,134.5,130.5,129.5,129.5,128.7,126.9,123.5,109.9,109.4,42.7,36.3ppm.
实施例9、WZY-ZX-0515的合成
WZY-ZX-0515:1)化合物X-5(100mg 0.43mmol),加入反反应瓶中,三乙胺(179.68μL1.29mmol),DCM溶解。加入g苯磺酰氯(179.68μL 1.29mmol),搅拌反应结束,反应液旋干,加1N盐酸调pH7-8,EA萃取,旋干,柱层析分离提纯得产物。收145.5mg,收率90.69%。
2):将X-8(145.5mg 0.39mmol)溶于EtOH:H2O1:1,加NaOH(47.06mg,1.18mmol),升温至70℃回流,0.5-1h,反应结束旋干乙醇,加加1N盐酸调pH7-8至5-6,EA萃取,旋干,柱层析加重结晶收90mg,收率64.57%.
1H NMR(400MHz,DMSO-d6)δ13.00(s,1H),8.36(d,J=12.00Hz,1H),8.00(d,J=8.40Hz,2H),7.85(d,J=6.80Hz,2H),7.69(d,J=8.40Hz,2H),7.59(m,3H),6.98(d,J=3.60Hz,1H),6.38(d,J=3.20Hz,1H)4.19(d,J=6.00Hz,2H)ppm
13C NMR(100MHz,DMSO-d6)δ167.4,152.1,141.2,134.2,132.7,130.4,129.5,126.9,123.6,111.1,109.1,39.9ppm.
实施例10、WZY-ZX-0703的合成
WZY-ZX-0703:将h烟酸(191.86mg,1.2mmol)加入反应瓶,用DCM溶解,搅拌下加入EDCI(274.29mg,1.43mmol),HOBT(208.57mg,1.43mmol),X-5(300mg,1.29mmol)然后室温下反应过夜,旋干加饱和碳酸氢钠溶液调pH至7-8,EA萃取,经柱层析得产品260.35mg,收率57.78%。
1H NMR(400MHz,DMSO-d6)δ9.30(t,J=10.80Hz,1H),9.07(d,J=1.60Hz,1H),8.73(d,J=6.00Hz,1H),8.25(t,J=8.00Hz,1H),8.00(d,J=8.40Hz,2H),7.81(d,J=8.40Hz,2H),7.53(d,J=12.40Hz,1H),7.11(d,J=3.60Hz,1H),6.52(d,J=3.20Hz,1H),4.61(d,J=5.60Hz,2H),4.31(m,2H),1.34(t,J=14.00Hz,3H)ppm.
13C NMR(100MHz,DMSO-d6)δ165.8,165.4,153.9,152.5,151.6,149.0,135.6,134.8,130.3,130.1,128.6,124.0,123.6,110.3,109.8,61.2,36.8,14.7ppm.
实施例11、WZY-ZX-0641的合成
WZY-ZX-0641:1)化合物X-4(1223.70mg 4.72mmol),加入反反应瓶中15mL甲醇溶解。0℃下加入NaBH3CN(504.22mg,1.7mmol)加入12M的盐酸(786.7μL 9.44mmol),RT搅拌4h反应结束,反应液旋干,加6N氢氧化钠水溶液调pH至9,EA萃取,旋干,柱层析分离提纯,得产物X-9(328mg)。
2)苯乙酸(900mg,6.61mmol)氯化亚砜(959.3μL.13.22mmol)DCM室温搅拌30min,旋干加入碳酸氢钠(588.07mg,7.0mmol)乙醚溶解,加入X-9,室温搅拌6h,的产物X-10.
3)X-10(66.7mg,0.20mmol)溶于EtOH:H2O1:1,加NaOH(31.47mg,0.79mmol),升温至60℃回流,0.5-1h,反应结束旋干乙醇,加加1N盐酸调pH7-8至5-6,EA萃取,旋干,柱层析加重结晶收45mg,收率67.46%。
1H NMR(400MHz,DMSO-d6)δ12.95(s,1H),10.15(s,1H),7.98(d,J=8.80Hz,2H)7.75(d,J=8.40Hz,2H),7.30(s,5H),7.28(s,5H),7.23(s,5H),7.08(d,J=3.20Hz,1H),6.49(d,J=3.20Hz,1H),4.80(s,2H),3.79(s,2H)ppm.
13C NMR(100MHz,DMSO-d6)δ167.4,152.0,151.8,136.1,134.4,130.5,129.9,129.6,128.6,126.8,123.6,111.7,109.4,45.07,38.9ppm.HRMS:m/z calcd for C20H16NO5[M-H]-350.1034,found 350.1066.
实施例12、ZX-0749的合成
ZX-0749:1)将9a(954.9μL,6.50mmol)溶于MeCN:H2O=1:1(20ml)的混合溶剂中,搅拌依次加入三苯基膦二氯化钯(228.05mg,0.325mmol),碳酸钠(1.377g,13.01mmol),5-甲醛基呋喃-2-硼酸(1.00g,7.15mmol),旋去乙腈,加1N盐酸调pH7-8,,EA萃取,有机层旋干得粗品,粗品经柱层析(PE:EA=5:1)分离得产物9c(1.5g,收率96.15%)。
2)取化合物9c(1.5g,6.25mmol)溶于15ml EtOH中,搅拌下加入盐酸羟胺(521.1mg,7.50mmol),无水NaOAC(615.05mg,7.5mmol),加毕,升温至80℃反应0.5h,旋去乙醇,EA溶解后,用水洗三次,有机层用无水硫酸钠干燥后旋干中间体9d;将9d溶于10ml乙醇中,搅拌下加入锌粉(2031.25mg,31.25mmol),3N的盐酸50ml,升温至80℃回流反应,0.5h后TLC检测,原料已反应完,趁热过滤剩余锌粉,旋去乙醇,水层调Ph至7-8,EA萃取三次,有机层用饱和食盐水水洗后旋干得粗品,粗品经柱层析(PE:EA=1:1)分离得9e。
3):将3-氨基吡啶(647.01mg,6.857mmol)和TEA(1.729ml,2.03mmol)溶于干燥的15mlDCM中,室温下缓慢滴加到三光气(1.854mg,6.25mmol)的无水DCM中,加毕,常温反应0.5h后,旋干,用干燥得DCM溶解,加入9e(100mg,0.43mmol),RT下反应6h旋干得粗品,经柱层析纯化得浅黄色固体(432.3mg,收率20.5%)。
1H NMR(400MHz,DMSO-d6)δ8.87(s,1H),8.58(s,1H),8.14(s,1H),7.91(d,J=12.80Hz,2H),7.87(s,1H),7.77(d,J=8.00Hz,2H),7.27(dd,J=12.80Hz,1H),7.11(d,J=3.20Hz,1H),6.89(t,J=11.20Hz,1H),6.46(d,J=3.20Hz,1H),4.41(d,J=5.60Hz,2H)ppm.
13C NMR(100MHz,DMSO)δ155.5,154.9,154.1,151.0,143.6,142.1,139.3,137.9,134.3,126.4,126.3,125.5,124.0,109.7,45.8ppm.
实施例14、W-LC-0435的合成
W-LC-0435:1)将1a(2g,7.24mmol)溶于MeCN:H2O=1:1(20ml)的混合溶剂中,搅拌依次加入三苯基膦二氯化钯(254mg,0.36mmol),碳酸钠(1.53g,14.48mmol),5-甲醛基呋喃-2-硼酸(2.01g,14.48mmol),加毕,升温至60℃反应,3停止反应,旋去乙腈,加水稀释,EA萃取,有机层旋干得粗品,粗品经柱层析(PE:EA=5:1)分离得黄褐色固体(1.3g,收率73.8%)。
2):取化合物1b(1g,4.1mmol)溶于15mlEtOH中,搅拌下加入盐酸羟胺(315mg,4.5mmol),无水NaOAC(372mg,4.5mmol),加毕,升温至80℃反应0.5h,TLC检测,停止反应,旋去乙醇,EA溶解后,用水洗三次,有机层用无水硫酸钠干燥后旋干中间体1c;将1c溶于10ml乙醇中,搅拌下加入锌粉(750mg,19.3mmol),3N的盐酸7ml,加毕,升温至80摄氏度回流反应,0.5h后TLC检测,原料已反应完,停止反应,趁热过滤剩余锌粉,旋去乙醇,水层调Ph至7-8,EA萃取三次,有机层用饱和食盐水水洗后旋干得粗品,粗品经柱层析(PE:EA=1:1)分离得黄色固体(0.45g,收率34.6%)。
3):将3-氨基吡啶(82mg,0.86mmol)和DIEA(0.28ml,1.73mmol)溶于干燥的2mlDCM中,室温下缓慢滴加到三光气(205mg,0.69mmol)的无水DCM中,加毕,常温反应0.5h后,旋干,用干燥得DCM溶解,加入1d(100mg,0.43mmol)和三乙胺(0.24ml,1.73mmol),加毕,升温至45摄氏度回流,1h后TLC检测,停止反应,旋干得粗品,经柱层析(DCM:MeOH=30:1)纯化得白色固体(120mg,收率82.7%)。
1H NMR(400MHz,DMSO-d6)δ9.45(s,1H),8.59(d,J=2.40Hz,1H),8.12(dd,J=4.00,Hz,1H),7.99(d,J=8.40Hz,2H),7.90(m,1H),7.82(d,J=8.00Hz,2H),7.26(m,1H),7.18(s,1H),7.10(d,J=3.20Hz,1H),6.46(d,J=3.20Hz,1H),4.40(d,J=5.60Hz,2H),4.32(q,J=8.40Hz,2H),1.33(t,J=8.40Hz,3H)ppm
实施例15、W-LC-0314的合成
W-LC-0314:取化合物W-LC-0435(120mg,0.34mmol)溶于10ml EtOH:H2O=2:1的混合溶剂中,加入氢氧化钠(41mg,1mmol),升温至60℃反应,2h后TLC检测,停止反应,旋去乙醇,水层调Ph至5-6左右,白色固体析出,过滤,水洗,干燥得白色固体(92mg,收率80%)。
1H NMR(400MHz,DMSO-d6)δ12.98(s,1H),8.84(s,1H),8.58(s,1H),8.14(d,J=4.00Hz,1H),7.99(d,J=8.40Hz,2H),7.93(d,J=8.40Hz,1H),7.79(d,J=8.00Hz,2H),7.29(d,J=12.80Hz,1H),7.08(d,J=3.20Hz,1H),6.87(t,J=5.60Hz,1H),6.45(d,J=3.20Hz,1H),4.41(d,J=5.60Hz,2H)ppm.
13C NMR(100MHz,DMSO-d6)δ167.5,155.4,154.7,151.6,142.7,140.1,137.5,134.5,130.5,129.5,125.2,124.1,123.5,109.8,109.5,31.2ppm.HRMS:m/z calcd forC18H16N3O4[M+H]+338.1135,found 338.1138
实施例16、W-LC-0337的合成
W-LC-0337:1)将异硫氰酸(0.1ml,0.78mmol)溶于干燥得DCM中,搅拌下加入1d(150mg,0.65mmol)和DIEA(0,2ml,1.3mmol),加毕,常温反应,2h后TLC检测,停止反应,旋干得粗品,经柱层析(PE:EA=4:1)纯化得白色固体(140mg,收率58.6%)。
2):取化合物3a(140mg,0.36mmol)溶于10mlEtOH:H2O=2:1的混合溶剂中,加入氢氧化钠(46mg,1.14mmol),升温至60℃反应,2h后TLC检测,停止反应,旋去乙醇,水层调Ph至5-6左右,白色固体析出,过滤,水洗,干燥得白色固体(120mg,收率89%)。
1H NMR(400MHz,DMSO-d6)δ11.04(s,1H),9.44(s,1H),7.95(d,J=8.40Hz,3H),7.70(d,J=8.40Hz,2H),7.64(d,J=8.00Hz,2H),7.30(t,J=8.00Hz,2H),7.07(d,J=8.40Hz,1H),6.96(d,J=3.20Hz,1H),6.48(d,J=3.20Hz,1H),4.82(d,J=5.60Hz,2H)ppm.
13C NMR(100MHz,DMSO-d6)δ207.0,181.4,169.6 152.9,152.4,140.7,132.7,130.3,128.7,124.0,123.1,110.1,108.1,31.2ppm.HRMS:m/z calcd for C19H17N2O3S[M+H]+353.0954,found 353.0962
实施例17、W-LC-0327的合成
W-LC-0327:1)将4-氨基-2-氟苄腈(94mg,0.69mmol)和DIEA(0.23ml,1.38mmol)溶于干燥的2mlDCM中,室温下缓慢滴加到三光气(164mg,0.55mmol)的无水DCM中,加毕,常温反应0.5h后,旋干,用干燥的DCM溶解,加入1d(80mg,0.3mmol)和三乙胺(0.19ml,1.38mmol),加毕,升温至45摄氏度回流,1h后TLC检测,停止反应,旋干得粗品,经柱层析(DCM:MeOH=30:1)纯化得淡黄色色固体(79mg,收率58%)。
2):取化合物4a(70mg,0.18mmol)溶于10mlEtOH:H2O=2:1的混合溶剂中,加入氢氧化钠(22mg,0.53mmol),升温至60℃反应,2h后TLC检测,停止反应,旋去乙醇,水层调Ph至6左右,有黄色固体析出,过滤,水洗,干燥得黄色固体(165mg,收率89%)。1H NMR(400MHz,DMSO-d6)δ10.97(s,1H),8.53(s,1H),7.96(d,J=8.40Hz,2H),7.83(d,J=12.80Hz,1H),7.70(d,J=8.40Hz,3H),7.41(d,J=8.40Hz,1H),6.93(d,J=3.20Hz,1H),6.41(d,J=3.20Hz,1H),4.40(d,J=5.60Hz,2H)ppm.
13C NMR(101MHz,DMSO-d6)δ207.0,169.6,165.0,162.5,155.2,153.6,152.4,148.45134.3,132.7,130.3,123.1,115.4,114.4,109.6,108.0,45.9ppm.HRMS:m/z calcdfor C20H14FN3O4[M+H]+380.1041,found 380.1040.
实施例18、W-LC-0436的合成
W-LC-0436:1)将5-溴-2-甲基吡啶-3-胺(150mg,0.8mmol)和DIEA(0.27ml,1.6mmol)溶于干燥的2mlDCM中,室温下缓慢滴加到三光气(195mg,0.64mmol)的无水DCM中,加毕,常温反应0.5h后,旋干,用干燥的DCM溶解,加入1d(150mg,0.64mmol)和三乙胺(0.23ml,1.6mmol),加毕,升温至45摄氏度回流,1h后TLC检测,停止反应,旋干得粗品,经柱层析(PE:EA=1:1)纯化得淡黄色色固体(195mg,收率67.7%)。
2):取化合物5a(190mg,0.41mmol)溶于10mlEtOH:H2O=2:1的混合溶剂中,加入氢氧化钠(52mg,1.33mmol),升温至60℃反应,2h后TLC检测,停止反应,旋去乙醇,水层调Ph至6左右,EA萃取得粗品,经柱层析纯化(DCM:MeOH=10:1)得黄色固体(165mg,收率92.7%)。
1H NMR(400MHz,DMSO-d6)δ12.96(s,1H),8.56(d,J=2.80Hz,1H),8.35(s,1H),8.14(d,J=2.80Hz,1H),7.98(d,J=8.40Hz,2H),7.80(d,J=8.40Hz,2H),7.58(s,1H),7.09(d,J=3.20Hz,1H),6.49(d,J=3.20Hz,1H),4.42(d,J=5.60Hz,2H),2.40(s,3H)ppm.
实施例19、W-LC-0421的合成
W-LC-0421:1)将6a(0.5g,1.7mmol)溶于MeCN:H2O=1:1(20ml)的混合溶剂中,搅拌依次加入三苯基膦二氯化钯(60mg,0.08mmol),碳酸钠(363g,3.4mmol),(5-甲酰基呋喃-2-基)硼酸(0.48g,3.4mol),加毕,升温至60℃反应,3h后TLC检测,旋去乙腈,加水稀释,EA萃取,有机层旋干得粗品,粗品经柱层析(PE:EA=10:1)分离得黄褐色固体(410mg,收率92.1%)。
2):取化合物6b(0.41g,1.57mmol)溶于10mlEtOH中,搅拌下加入盐酸羟胺(130mg,1.89mmol),无水NaOAC(155mg,1.89mmol),加毕,升温至80℃反应0.5h,TLC检测原料已反应完,停止反应,旋去乙醇,EA溶解后,用水洗三次,有机层用无水硫酸钠干燥后旋干中间体6c;将6c溶于10ml乙醇中,搅拌下加入锌粉(512mg,7.8mmol),3N的盐酸6ml,加毕,升温至80℃回流反应,0.5h后TLC检测,原料已反应完,停止反应,趁热过滤剩余锌粉,旋去乙醇,水层调Ph至7-8,EA萃取三次,有机层用饱和食盐水水洗后旋干得粗品,粗品经柱层析(PE:EA=2:1)分离得黄色固体(232mg,收率53.3%)。
3):将苯胺(100mg,1.07mmol)和DIEA(0.36ml,2.14mmol)溶于2ml干燥的DCM中,室温下缓慢滴加到三光气(260mg,0.86mmol)的无水DCM中,加毕,常温反应0.5h后,旋干,用干燥的DCM溶解,加入6d(210mg,0.8mmol)和三乙胺(0.3ml,2.14mmol),加毕,升温至45℃回流,1h后TLC检测,停止反应,旋干得粗品,经柱层析(DCM:MeOH=30:1)纯化得白色固体(150mg,收率51%)。
4):化合物6e(150mg,0.41mmol)溶于10mlEtOH:H2O=2:1的混合溶剂中,加入氢氧化钠(44mg,1.1mmol),升温至60℃反应,2h后TLC检测,停止反应,旋去乙醇,水层调Ph至6左右,有白色固体析出,过滤,水洗,干燥得白色固体(56mg,收率40.3%)。1H NMR(400MHz,DMSO-d6)δ8.60(s,1H),7.82(d,J=8.5Hz,1H),7.42(d,J=8.00Hz,2H),7.24(d,J=12.80Hz,4H),7.10(d,J=3.20Hz,1H),6.91(s,1H),6.68(s,1H),6.43(d,J=3.20Hz,1H),4.38(d,J=5.60Hz,2H)ppm.
13C NMR(100MHz,DMSO-d6)δ172.1,162.1,155.5,155.2,151.2,140.8,137.0,131.5,129.2,121.7,118.3,114.6,111.9,111.1,110.2,109.6,36.9ppm.HRMS:m/z calcdfor C19H16N2O5[M+H]+353.1132found 353.1140.
实施例20本发明化合物对SIRT1和SIRT2蛋白的抑制活性
1)实验材料:
购买于BPS公司的组蛋白去乙酰化酶(HDAC)缓冲液(产品编号:50031);BPS公司的SIRT显影剂(产品编号:50089);杭州丹港生物科技合成的SIRT蛋白底物以及多个受试化合物。
2)实验方法:
首先,制备反应母液:于每个测试孔中加入5ul牛血清白蛋白(BSA,1mg/ml),0.5mM烟酰胺腺嘌呤二核苷酸(NAD+,1mg/ml),14.5μLSIRT缓冲溶液和5μl稀释的SIRT底物(100μM/L)。然后,将所有受试化合物溶解于100%的DMSO中配制成10mM/L的溶液后用含有10%DMSO的HDAC缓冲溶液分别将其稀释成100μM/L、10μM/L。随后,取配制好化合物溶液5μl,加入不同的测试孔中;再向每个测试孔中加入20μlSIRT1/2蛋白后于37℃下培养30分钟。接着,每孔中加入50μl的2x SIRT显影剂于常温继续培养15min。最后使用Biotek Synergy酶标仪在激发光为380nM和440nM发射光波长处测试以上反应液的发光强度从而根据“抑制活性%=(F-Fb)/(Ft-Fb)x 100%”确定化合物对SIRT1/2的抑制活性,其中F为含有受试化合物的荧光强度,Fb为不含SIRT蛋白的荧光强度;Ft为不含测受试化合物的荧光强度。
3)实验结果:
通过以上实验方法,测试了本发明中的化合物针对SIRT1和SIRT2的抑制活性。具体部分化合物在10μM、100μM浓度下的抑制活性见表1.其中A表示抑制率大于85%、B表示抑制率为50%-84%、C表示抑制率为30%-49%,D表示抑制率小于30%;-表示未测试。
表1.受试化合物对SIRT1和SIRT2的抑制活性
综上所述,本发明提供的2,5-双取代呋喃衍生物,该2,5-双取代呋喃衍生物主要为2-位取代胺甲基,5-位取代苯基,同时对SIRT1和SIRT2蛋白具有优异的抑制作用,可以用于治疗多种疾病,如肿瘤、神经退行性疾病、代谢性疾病等。
Claims (11)
1.一种化合物或其药学上可接受的盐,所述化合物的结构如式(I)所示:
其中:
R1为取代苯基,所述取代苯基被一个或多个选自-COOH、-COOR4、-OH、-CX3、-CHX2、 -CH2X的取代基所取代;R4选自C1~C6烷基;
R2选自H或-OH;
R3选自-COR5、-CSNHR8;
R5选自取代或非取代苯基或吡啶基、-NHR9、-(CH2)aR10;所述苯基或吡啶基独立地被一个或多个C1~C6烷基的取代基所取代;
R8为苯基;
R9选自取代或非取代苯基或吡啶基,所述苯基或吡啶基分别独立地被一个或多个选自-X、-CN、-CX3、-CHX2、-CH2X、C1~C6烷基的取代基所取代;R10 为苯基;
X表示 F、Cl、Br或I;a=1或2。
2.根据权利要求1所述化合物或其药学上可接受的盐,其特征在于:所述R1中,C1~C6烷基选自乙基。
3.根据权利要求1所述化合物或其药学上可接受的盐,其特征在于:所述R1中,苯基取代基为-COOH。
4.根据权利要求1-3任一项所述化合物或其药学上可接受的盐,其特征在于:所述R2选自H。
8.根据权利要求7所述的方法,其特征在于:所述金属催化剂为钯催化剂。
9.根据权利要求8所述的方法,其特征在于:所述金属催化剂为三苯基膦二氯化钯。
10.根据权利要求1-6任一项所述化合物或其药学上可接受的盐在制备沉默信息调节因子2蛋白抑制剂类药物上的用途,其特征在于:所述沉默信息调节因子2蛋白抑制剂类药物是SIRT1和SIRT2抑制剂类药物。
11.根据权利要求10所述的用途,其特征在于:所述药物是治疗或预防代谢性疾病、肿瘤或神经退行性急性病的药物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811386729.1A CN109293606B (zh) | 2018-11-20 | 2018-11-20 | 2,5-双取代呋喃衍生物及其作为sirt蛋白抑制剂在药物制备中的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811386729.1A CN109293606B (zh) | 2018-11-20 | 2018-11-20 | 2,5-双取代呋喃衍生物及其作为sirt蛋白抑制剂在药物制备中的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109293606A CN109293606A (zh) | 2019-02-01 |
CN109293606B true CN109293606B (zh) | 2022-07-12 |
Family
ID=65144744
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811386729.1A Active CN109293606B (zh) | 2018-11-20 | 2018-11-20 | 2,5-双取代呋喃衍生物及其作为sirt蛋白抑制剂在药物制备中的用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109293606B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112939955B (zh) * | 2021-03-05 | 2022-10-21 | 朗捷睿(苏州)生物科技有限公司 | 一种8-(吡啶酰胺)取代香豆素类化合物及其制备方法和应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102970867A (zh) * | 2010-03-18 | 2013-03-13 | 拜耳知识产权有限责任公司 | 作为活性剂对抗非生物植物应激的芳基和杂芳基磺酰胺 |
CN103393683A (zh) * | 2013-06-24 | 2013-11-20 | 上海交通大学医学院附属瑞金医院 | Sirt2抑制剂在制药中的应用 |
CN106977474A (zh) * | 2017-05-10 | 2017-07-25 | 四川大学 | 一种取代2‑氰基‑3‑苯基呋喃‑丙烯酰胺衍生物及其制备方法和用途 |
WO2018162785A2 (es) * | 2017-03-10 | 2018-09-13 | Universidad De Granada | Compuestos para el tratamiento de enfermedades causadas por la acumulación de oxalato |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080021063A1 (en) * | 2006-07-18 | 2008-01-24 | Kazantsev Aleksey G | Compositions and methods for modulating sirtuin activity |
US8153803B2 (en) * | 2006-07-18 | 2012-04-10 | The General Hospital Corporation | Compositions and methods for modulating sirtuin activity |
-
2018
- 2018-11-20 CN CN201811386729.1A patent/CN109293606B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102970867A (zh) * | 2010-03-18 | 2013-03-13 | 拜耳知识产权有限责任公司 | 作为活性剂对抗非生物植物应激的芳基和杂芳基磺酰胺 |
CN103393683A (zh) * | 2013-06-24 | 2013-11-20 | 上海交通大学医学院附属瑞金医院 | Sirt2抑制剂在制药中的应用 |
WO2018162785A2 (es) * | 2017-03-10 | 2018-09-13 | Universidad De Granada | Compuestos para el tratamiento de enfermedades causadas por la acumulación de oxalato |
CN106977474A (zh) * | 2017-05-10 | 2017-07-25 | 四川大学 | 一种取代2‑氰基‑3‑苯基呋喃‑丙烯酰胺衍生物及其制备方法和用途 |
Non-Patent Citations (3)
Title |
---|
Discovery of 2-((4,6-dimethylpyrimidin-2-yl)thio)-Nphenylacetamide derivatives as new potent and selective human sirtuin 2 inhibitors;Lingling Yang,et al.;《European Journal of Medicinal Chemistry》;20170412;第134卷;第230-241页 * |
REGISTRY数据库(STN);无;《REGISTRY数据库(STN)》;20180330;第1-10页 * |
Ring-chain tautomerism in the products of the reaction between 5-substituted furfurylamines and anhydrides of α,β-unsaturated carboxylic acids;Zubkov, Fedor I.,et al.;《Chemistry of Heterocyclic Compounds》;20160120;第52卷(第4期);第225-236页 * |
Also Published As
Publication number | Publication date |
---|---|
CN109293606A (zh) | 2019-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7266538B2 (ja) | Fxr受容体作動薬としてのラクタム系化合物 | |
TWI296625B (en) | Novel cyclic amide derivatives | |
JP6351182B2 (ja) | ガンの治療方法 | |
CA2741666C (en) | P2x3, receptor antagonists for treatment of pain | |
EP2704701B1 (en) | Compounds for inflammation and immune-related uses | |
WO2012070114A1 (ja) | Npy y5受容体拮抗作用を有するスルファミド誘導体 | |
JP2015536308A5 (zh) | ||
KR20120003941A (ko) | 신규 갑상선 호르몬 β 수용체 작동약 | |
JP2010523644A (ja) | 抗がん活性を有する化合物 | |
CN111051300B (zh) | 作为组蛋白脱乙酰基酶1和/或2(hdac1-2)的选择性抑制剂的新杂芳基酰胺衍生物 | |
EP3509588A1 (en) | Bicyclic compounds useful as gpr120 modulators | |
CA2721576A1 (en) | Compound having npy y5 receptor antagonist activity | |
CN109293606B (zh) | 2,5-双取代呋喃衍生物及其作为sirt蛋白抑制剂在药物制备中的用途 | |
KR20150002713A (ko) | 단백질 응집 저해제로서의 페닐-우레아 및 페닐-카바메이트 유도체 | |
CN114539267A (zh) | 一种吴茱萸碱衍生物及其应用 | |
WO2021238007A1 (zh) | 可诱导prc2蛋白复合物核心亚基降解的双功能化合物和药物组合物及应用 | |
WO2015018182A1 (zh) | 苯乙酸衍生物及其抗肿瘤用途 | |
AU2020424661B2 (en) | Disubstituted adamantyl derivative or pharmaceutically acceptable salt thereof, and pharmaceutical composition for suppressing cancer growth comprising same as active ingredient | |
CN113563319B (zh) | 具有磷酸二酯酶4b抑制活性的吲唑杂环类化合物 | |
EP2240443A1 (en) | Proline analogs as ligands for cannabinoid receptors for the treatment of pain | |
CN107556316B (zh) | 含桥环的咪唑衍生物 | |
CN113248482B (zh) | 含苯并五元杂环结构的化合物及其制备方法与用途 | |
WO2013063385A1 (en) | Compounds for inflammation and immune-related uses | |
WO2012064808A1 (en) | Tetrazolyl - tetrahydropyridine compounds for inflammation and immune - related uses | |
CN114585606A (zh) | 抑制perk的化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |